Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sets New 1-Year High – Here’s What Happened

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)’s share price hit a new 52-week high during trading on Tuesday . The stock traded as high as $76.76 and last traded at $75.8610, with a volume of 1969376 shares trading hands. The stock had previously closed at $63.88.

Trending Headlines about Arrowhead Pharmaceuticals

Here are the key news stories impacting Arrowhead Pharmaceuticals this week:

• Positive Sentiment: Interim Phase 1/2a data for RNAi obesity candidates ARO‑INHBE and ARO‑ALK7 showed meaningful weight loss and reductions in visceral fat, total fat and liver measures — results that validate Arrowhead’s RNAi approach in metabolic disease and expand commercial/partnership value if confirmed in later trials. BusinessWire: Interim clinical data
• Positive Sentiment: Arrowhead reported its gene‑silencing add‑on nearly doubled four‑month weight loss versus tirzepatide (Zepbound) alone — a headline result that could drive strong investor enthusiasm around combination potential and pipeline upside in obesity. Investors.com: Gene silencer doubled weight loss
• Positive Sentiment: Health Canada granted a Notice of Compliance for REDEMPLO™ (plozasiran) to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS) — a commercial regulatory win that enables initial revenue in Canada and validates Arrowhead’s siRNA platform in a rare disease indication. BusinessWire: Health Canada approval
• Neutral Sentiment: Analyst activity remains constructive: several firms raised price targets and the consensus remains a “Moderate Buy,” which supports sentiment but already appears priced in after recent upgrades. MarketBeat: analyst coverage
• Negative Sentiment: Significant insider selling disclosed this week: CEO Christopher Anzalone sold 13,187 shares (filed with SEC), while other insiders including James C. Hamilton (40,164 shares) and COO Patrick O’Brien (49,493 shares) also sold sizable blocks — trades that can create investor concern about near‑term selling pressure or portfolio diversification. InsiderTrades: CEO sale SEC: Hamilton Form 4 SEC: O’Brien Form 4

Analyst Ratings Changes

A number of brokerages have weighed in on ARWR. Morgan Stanley lifted their price target on shares of Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 26th. Bank of America upped their price target on Arrowhead Pharmaceuticals from $62.00 to $81.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. HC Wainwright boosted their price objective on Arrowhead Pharmaceuticals from $80.00 to $85.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. Royal Bank Of Canada increased their target price on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the stock an “outperform” rating in a research note on Thursday, December 11th. Finally, The Goldman Sachs Group lifted their target price on Arrowhead Pharmaceuticals from $27.00 to $48.00 and gave the company a “neutral” rating in a research report on Thursday, November 20th. Two investment analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $61.89.

Arrowhead Pharmaceuticals Price Performance

The company has a 50 day moving average of $55.20 and a 200 day moving average of $35.35. The company has a debt-to-equity ratio of 0.43, a quick ratio of 4.86 and a current ratio of 4.86. The stock has a market capitalization of $10.13 billion, a price-to-earnings ratio of -934.10 and a beta of 1.21.

Insider Activity

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 130,000 shares of the business’s stock in a transaction that occurred on Monday, December 15th. The shares were sold at an average price of $68.85, for a total transaction of $8,950,500.00. Following the completion of the transaction, the chief executive officer owned 3,971,255 shares in the company, valued at $273,420,906.75. The trade was a 3.17% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider James C. Hamilton sold 40,164 shares of the firm’s stock in a transaction on Monday, January 5th. The shares were sold at an average price of $63.11, for a total transaction of $2,534,750.04. Following the completion of the sale, the insider owned 171,958 shares in the company, valued at $10,852,269.38. The trade was a 18.93% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 510,836 shares of company stock worth $33,603,060 over the last three months. Insiders own 4.30% of the company’s stock.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Arrowhead Pharmaceuticals by 138.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,785,062 shares of the biotechnology company’s stock valued at $60,962,000 after purchasing an additional 2,774,933 shares in the last quarter. Marshall Wace LLP grew its position in shares of Arrowhead Pharmaceuticals by 3,507.8% in the 2nd quarter. Marshall Wace LLP now owns 2,155,998 shares of the biotechnology company’s stock valued at $34,065,000 after buying an additional 2,096,238 shares during the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Arrowhead Pharmaceuticals by 3,142.5% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 2,081,689 shares of the biotechnology company’s stock worth $71,797,000 after acquiring an additional 2,017,489 shares in the last quarter. Norges Bank purchased a new stake in Arrowhead Pharmaceuticals in the second quarter valued at $30,414,000. Finally, Deerfield Management Company L.P. acquired a new position in Arrowhead Pharmaceuticals in the third quarter valued at $34,249,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.